Relationship between inflammatory mediators, Aβ levels and ApoE genotype in Alzheimer disease

Current Alzheimer Research

Volumn 9, Issue 4, 2012, Pages 447-457

  Reale, M ^a   Kamal, M A ^b   Velluto, L ^c   Gambi, D ^a   di Nicola, M ^a   Greig, N H ^d  

^a UNIVERSITY OF CHIETI   (Italy)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c Center of Sleep Medicine Villa Serena Hospital   (Italy)

^d Drug Design and Development Section   (United States)

Author keywords

Alzheimer's disease; Amyloid peptide; ICAM 1; IL 18; IL 18BP; MCP 1; Neuroinflammation; RANTES; THP 1

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; MALE; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84860501544     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512800492549     Document Type: Article

References (66)

1. Zlokovic BV. Cerebrovascular transport of Alzheimer's amyloid-b and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain-barrier. Life Sci 59: 1483-97 (1996).
2. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 16: 903-7 (2011)
3. Giri R, Shen Y, Stins M, Yan SD, Schmidt AM, Stern D, et al. β-Amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol 279: C1772-C1781 (2000).
4. Kerschensteiner M, Meinl E, Hohlfeld R. Neuro-immune crosstalk in CNS diseases. Neuroscience 158: 1122-32 (2009).
5. Tripathy D, Thirumangalakudi L, Grammas P. RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role. Neurobiol Aging 31: 8-16 (2010).
6. Conductier G, Blondeau N, Guyon A, Nahon JL, Rovère C. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 224: 93-100 (2010).
7. Karpus WJ. Chemokines and central nervous system disorders. J Neurovirol 7: 493-500 (2001).
8. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347: 669-71 (1990).
9. Sandmand M, Bruunsgaard H, Kemp K, Andersen-Ranberg K, Pedersen AN, Skinhøj P, et al. Is ageing associated with a shift in the balance between Type 1 and Type 2 cytokines in humans? Clin Exp Immunol 127: 107-14 (2002).
10. Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin-18 (IFNg-inducing factor) induces IL-8 and IL-1b via TNF-a production from non-CD14% human blood mononuclear cells. J Clin Invest 101: 711-21 (1998).
11. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J, et al. IL-18 regulates IL-1-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 97: 734-9 (2000).
12. Stuyt RJ, Netea MG, Geijtenbeek TB, Kullberg BJ, Dinarello CA, van der Meer JW. Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes. Immunology 110: 329-34 (2003).
13. Ojala J, Alafuzoff I, Herukka S, Van Groen T, Tanila H, Pirttila T. Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiol Aging 30: 198-209 (2009).
14. Reznikov LL, Kim SH, Zhou L, Bufler P, Goncharov I, Tsang M, Dinarello CA. The combination of soluble IL-18Ralpha and IL18Rbeta chains inhibits IL-18-induced IFN-gamma. J. Interferon Cytokine Res 22: 593-601 (2002).
15. Diagnostic and Statistical Manual of Mental Disorders (4th ed.), American Psychiatric Association, Washington, D.C. (1994).
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-44 (1984).
17. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-98 (1975).
18. Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z, Keane WF, Chvatchko Y, Kim SH, Fantuzzi G, Dinarello CA, Rubinstein M. A novel IL-18BP ELISA shows elevated serum IL18BP in sepsis and extensive decrease of free IL-18. Cytokine 14: 334-42 (2001).
19. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest 97: 77-89 (1968).
20. Iarlori C, Gambi D, Gambi F, Lucci I, Feliciani C, Salvatore M, Reale M. Expression and production of two selected betachemokines in peripheral blood mononuclear cells from patients with Alzheimer's disease. Exp Gerontol 40: 605-11 (2005).
21. Rentzos M, Michalopoulou M, Nikolaou C, Cambouri C, Rombos A, Dimitrakopoulos A, et al. The role of soluble intercellular adhesion molecules in neurodegenerative disorders. J Neurol Sci 228: 129-35 (2005).
22. Metha PD, Pirtila T, Patrick BA, Barshatzky, Metha SP. Amiloid bprotein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 304: 101-6 (2001).
23. Blennow K, De Meyer G, Hansson O, Minthon L, Wallin A, Zetterberg H, et al. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging 13: 205-8 (2009).
24. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 58: 681-93 (2008).
25. Reale M, Patruno A, De Lutiis MA, Pesce M, Felaco M, Di Giannantonio M, et al. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 12: 13 (2011).
26. Zuliani G, Ranzini M, Guerra G, Rossi L, Munari MR, Zurlo A, Volpato S, et al. Plasma cytokine profile in older subjects with late onset Alzheimer's disease or vascular dementia. J Psychiatric Res 41: 686-93 (2007).
27. Di Bona D, Plaia A, Vasto S, Cavallone L, Lescai F, Franceschi C, et al. Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. Brain Res Rev 59: 155-63 (2008).
28. Di Rosa M, Dell'Ombra N, Zambito AM, Malaguarnera M, Nicoletti F, Malaguarnera L. Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementia. Eur J Neurosci 23: 2648-56 (2006).
29. Bossu P, Ciaramella A, Moro ML, Bellincampi L, Bernardini S, Federici G, et al. Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer's disease. J Neurol Neurosurg Psychiatry 78: 807-11 (2007).
30. Reale M, Iarlori C, Gambi F, Feliciani C, Salone A, Toma L, et al. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the proinflammatory and anti-inflammatory cytokines. J Neuroimmunol 148: 162-71 (2004).
31. Reale M, Greig NH, Kamal MA. Peripheral chemo-cytoines profiles in alzheimer's and Parkinson's disease. Mini-Reviews Med Chem 9: 1229-41 (2009).
32. Dinarello CA. Interleukin-18, a proinflammatory cytokine. Eur Cytokine Netw 11: 483-6 (2000).
33. Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr 83: 447S-455S (2006).
34. Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 27: 98-114 (2007).
35. Nakanishi KA, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19: 423-74 (2001).
36. Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 101: 711-21 (1998).
37. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 223: 20-38 (2008).
38. Frohman EM, Frohman TC, Gupta S, de Fougerolles A, van den Noort S. Expression of intercellular adheion molecule 1 (ICAM-1) in Alzheimer's disease. J Neurol Sci 106: 105-11 (1991).
39. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation in Alzheimer's disease. Neurobiol Aging 21: 383-421 (2000).
40. Merendino RA, Di Pasquale G, Sturniolo GC, Ruello A, Albanese V, Minciullo PL, et al. Relationship between IL-18 and sICAM-1 serum levels in patients affected by coeliac disease: preliminary considerations. Immunol Lett 85: 257-60 (2003).
41. Perejaslov A, Chooklin S, Bihalskyy I. Implication of interleukin 18 and intercellular adhesion molecule (ICAM)-1 in acute pancreatitis. Hepatogastroenterology 55: 1806-13 (2008).
42. Takahashi HK, Iwagaki H, Yoshino T, Yoshino T, Mori S, Morichika T, et al. Prostaglandin E2 inhibits IL-18-induced ICAM1 and B7.2 expression through EP2/EP4 receptor in human peripheral blood mononuclear cells. J Immunol 168: 4446-4554 (2002).
43. Lee SJ, Drabik K, Van Wagoner NJ, Lee S, Choi C, Dong Y, et al. ICAM-1-induced expression of proinflammatory cytokines in astrocytes: involvement of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways. J Immunol 165: 4658-66 (2000).
44. Miller DW. Immunobiology of the blood-brain barrier. J Neurovirol 5: 570-8 (1999).
45. Reale M, Iarlori C, Gambi F, Feliciani C, Isabella L, Gambi D. The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients. Neuropharmacology 50: 606-13 (2006).
46. D'Ambrosio D, Iellem A, Colantonio L, Clissi B, Pardi R, Sinigaglia F. Localizzation of Th-cell subsets in inflammation:differential thresholds for extravasion of Th1 and Th2 cells. Immunol Today 21: 183-6 (2000).
47. Appay V, Rowland-Jones SL. RANTES: a versatile and controversial chemokine. Trends Immunol 22: 83-7 (2001).
48. Naert G, Rivest S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Neurosci 31: 6208-20 (2011).
49. Lahiri DK, Sambamurti K, Bennett DA. Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease. Neurobiol Aging 25: 651-60 (2004).
50. Gafencu AV, Robciuc MR, Fuior E, Zannis VI, Kardassis D, Simionescu M. Inflammatory signaling pathways regulating ApoE gene expression in macrophages. J Biol Chem 282: 21776-85 (2007).
51. Finch CE, Morgan TE. Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr Alzheimer Res 4: 185-9 (2007).
52. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch.Neurol 57: 100-5 (2000).
53. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, et al. Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61: 1185-90 (2003).
54. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, et al. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 27: 904-5 (2006).
55. Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, et al Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci 141: 65-8 (1996).
56. Frankfort SV, van Campen JPCM, Tulner LR, Beijnen JH. Serum amyloid beta peptides in patients with dementia and age-matched non-demented controls as detected by surface-enhanced laser desorption ionisation-time of flight mass spectrometry (SELDITOF MS). Curr Clin Pharmacol 3: 144-52 (2008).
57. Ertekin-Taner N, Younkin LH, Yager DM, Parfitt F, Baker MC, Asthana S, et al. Plasma amyloid beta protein is elevated in lateonset Alzheimer disease families. Neurology 70: 596-606 (2008).
58. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64: 354-62 (2007).
59. Chen M, Inestrosa NCK, Ross, GS, Fernandez, HL. Platelets are the primary source of Aβ peptide in human blood. Biochem. Biophys. Res Comm 2139: 6-103 (1995).
60. Evin G, Zhu A, Holsinger D, Masters CL, Li QX. Proteolytic processing of the Alzheimer's Disease amyloid precursor protein in brain and platelets. J Neurosci Res 74: 386-92 (2003).
61. Beher D, Wrigley JD, Owens AP, Shearman MS. Generation of Cterminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. J Neurochem 82: 563-75 (2002).
62. Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4: 191-7 (2007).
63. Eglitis MA, Mezey E. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci USA 94: 4080-5 (1997).
64. Giri R, Selvaraj SK, Kalra VK. Amyloid Peptide-Induced Cytokine and Chemokine Expression in THP-1 Monocytes Is Blocked by Small Inhibitory RNA Duplexes for Early Growth Response-1 Messenger RNA J Immunol 170: 5281-94 (2003).
65. Smits HA, van Beelen AJ, de Vos NM, Rijsmus A, van der BT, Verhoef J, et al. Activation of human macrophages by amyloid-β is attenuated by astrocytes. J Immunol 166: 6869-76 (2001).
66. Lindberg C, Chromek M, Ahrengart L, Brauner A, Schultzberg M, Garlind A. Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease. Neurochem Int 46: 551-7 (2005).